Drug Profile
JNJ 10229570 AAA
Alternative Names: JNJ-10229570; JNJ-10229570-AAA; MC 5 - Ortho Dermatologics; MC5-RA - Ortho DermatologicsLatest Information Update: 02 Aug 2017
Price :
$50
*
At a glance
- Originator Ortho Dermatologics
- Developer Valeant Pharmaceuticals International
- Class Antiacnes
- Mechanism of Action Melanocortin type 5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne vulgaris
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 12 Dec 2011 Valeant Pharmaceuticals acquires Ortho Dermatologics
- 29 Nov 2011 Johnson and Johnson completes enrolment in its phase II trial for Acne vulgaris in USA (NCT01326780)